Allogene Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$1.15(as of Sep 5, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Allogene Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$1.15
Ticker SymbolALLO
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees226
CountyUSA
Market Cap$255.2M
EBIDTA-228.5M
10-Day Moving Average1.15
P/E Ratio-1.06
20-Day Moving Average1.11
Forward P/E Ratio0.00
50-Day Moving Average1.20
Earnings per Share-1.10
200-Day Moving Average1.59
Profit Margin-Infinity%
RSI50.12
Shares Outstanding221.9M
ATR0.09
52-Week High3.78
Volume2,359,248
52-Week Low0.86
Most Recent Support Level1.06
Book Value344.6M
Most Recent Resistance Level1.21
P/B Ratio0.73
Upper Keltner1.31
P/S Ratio-11,444.05
Lower Keltner0.90
Debt-to-Equity Ratio1.31
Next Earnings Date10/30/2025
Cash Surplus20.7M
Next Ex-Dividend DateUnknown

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics Inc In Our Stock Scanner

As of Sep 08, 2025
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Discounted Stocks with Earnings GrowthScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Falling WedgeScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.